At a glance
ClinicalIndex Comparison RecordN/ACompleted· 375 enrolled
Drug / intervention
dexamethasone intravitreal implantdrug
Likely dose
dexamethasone intravitreal implant 700 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Retinal Vein Occlusion
In Brief
An observational study evaluating dexamethasone intravitreal implant for Macular Edema and Retinal Vein Occlusion. Completed, enrolled 375 participants across 1 site.
Detailed Summary
Epidemiological study of Ozurdex® in sites treating patients with retinal vein occlusion.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Edema, Retinal Vein Occlusion
CountriesFrance
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2011
First PostedJun 2012
Primary CompletionApr 2013
Study CompletionOct 2014
TodayJul 2026
First PostedJun 13, 2012
Enrollment StartNov 1, 2011
Primary CompletionApr 1, 2013
Study CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 14.1 years ago
Interventions
dexamethasone intravitreal implantdrug
dexamethasone intravitreal implant 700 μg administered into the eye according to physician judgment.